Haemodynamic changes measured by transthoracic bioimpedance during treatment with recombinant human erythropoietin.
Hypertension complicates the treatment of anaemia of chronic renal failure with recombinant human erythropoietin (EPO) in some patients. We conducted a prospective study measuring changes in cardiac index (CI) and systemic vascular resistance index (SVRI) in 29 patients from before commencement of EPO to attainment of target haemoglobin concentration. We used the operator-independent technique of trans-thoracic bioimpedance. The group of patients who developed EPO-induced hypertension (EpHT) were separately analysed and compared with the group who had no change in blood pressure (NC). Our results showed there was a significant rise in SVRI after treatment in EpHT group patients but in the NC group there was a small fall. CI increased significantly in the NC group after treatment but no change was recorded in the EpHT group. These findings clearly demonstrate how the cardiovascular changes differ in patients who develop EPO-induced hypertension.
Jones
M A
MA
Trafford Department of Renal Medicine, Royal Sussex County Hospital, Brighton, United Kingdom.
Kingswood
J C
JC
Dallyn
P E
PE
Sharpstone
P
P
D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D001794:Blood Pressure / Q000502:physiology; D002307:Cardiography, Impedance / Q000379:methods; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000503:physiopathology*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011187:Posture; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D006435:Renal Dialysis; D014655:Vascular Resistance / Q000502:physiology
D011994:Recombinant Proteins; D004921:Erythropoietin